failed_experiment.db
← Back to browse

Medicine› Cardiology and Cardiovascular Medicine› Heart Failure Treatment and Management

Heart failure — Mineralocorticoid receptor (spironolactone)

Submitted 2026-10-22

Field: Medicine › Cardiology and Cardiovascular MedicineType: No effect foundArea: heart failureArea: cardiovascular diseaseTarget: Mineralocorticoid receptor (spironolactone)Stage: randomized trial

Hypothesis

Spironolactone, which improves outcomes in heart failure with reduced ejection fraction, would do the same in heart failure with preserved ejection fraction.

What failed

In 3,445 patients with ejection fraction of 45% or more over a mean 3.3 years, the primary composite (cardiovascular death, aborted cardiac arrest or heart-failure hospitalization) occurred in 18.6% vs 20.4% on placebo (HR 0.89, P=0.14). Hyperkalemia doubled (18.7% vs 9.1%).

Broken assumption

Mineralocorticoid-receptor blockade helps heart failure with preserved ejection fraction the way it helps reduced ejection fraction.

Why

A benefit established in reduced ejection fraction did not carry over to preserved ejection fraction on the primary endpoint; only heart-failure hospitalization, one component, fell significantly (12.0% vs 14.2%).

From the published paper: Pitt B, Pfeffer MA, Assmann SF, et al. (TOPCAT). N Engl J Med, 2014. NCT00094302 ↗

Research ideas from this failure

Unvetted lead — read the papers

New hypotheses this failure suggests, each with a crucial experiment, a rival explanation of the original result, and the papers it rests on. Written by AI from paper titles and abstracts found on OpenAlex (and Europe PMC, for life and health sciences).

Related failures (5)

Matched on shared genes, mechanisms and ways of failing as well as wording. Each shows why it matched — treat these as leads rather than verdicts.

Links in published research

Where this experiment's genes are known to matter outside its own research area, and the papers behind those links. Sources: Open Targets Platform and Europe PMC.